Allison Wu, MD, MPH, is a general pediatric gastroenterologist at Boston Children’s Hospital and an assistant professor of pediatrics at Harvard Medical School.

How Food Access Shapes Childhood Obesity Risk

 remains one of the most pressing public health challenges in the United States, with growing recognition that its roots extend far beyond individual behavior. Increasing attention is being turned to the broader food environment, both at the neighborhood and household levels, as a key driver of long-term health outcomes.

0:00:13 – Defining food access vs food availability

0:01:0 – Study design and main findings

0:02:40 – Critical windows for intervention

0:04:05 – Role of gastroenterologists and team-based care

0:05:15 – Policy and “food is medicine” advocacy

New research presented by Allison Wu, MD, MPH, a general pediatric gastroenterologist at Boston Children’s Hospital and an assistant professor of pediatrics at Harvard Medical School​, at Digestive Disease Week (DDW) 2026 offers important insight into how these factors intersect to shape obesity risk over time.

In a large retrospective cohort study of nearly 14,000 children aged 2 to 11 years across Mass General Brigham-affiliated sites, she and colleagues examined how neighborhood food access and household food security influence body mass index (BMI) trajectories and obesity risk. Using geocoded residential data linked to the USDA Food Access Research Atlas, the study identified children living in low-income, low-vehicle (LILV) neighborhoods, areas where access to supermarkets is limited.

Over a 5-year follow-up period spanning 2019 to 2024, residence in these neighborhoods was associated with significantly higher BMI z-scores and an increased risk of obesity.

Of note, these effects were not immediate but emerged over time. Children living in LILV neighborhoods had a nearly 2-fold increased risk of obesity by age 10 compared to peers in areas with better food access, even after adjusting for insurance status. Parallel findings were observed at the household level, where children from food-insecure households also demonstrated higher BMI trajectories and elevated obesity risk, reinforcing the independent and additive roles of these exposures.

The study also underscores the importance of timing in intervention strategies. While differences in BMI were not apparent in early childhood, disparities became significant later, particularly in older children and adolescents. This suggests that early life remains a critical window for prevention, even before measurable differences emerge.

“I think of the critical windows for intervention as 2-fold. One is in early childhood thinking of obesity prevention. Even though we didn't see these effects at age 5, obesity prevention needs to be an area of focus, so intervening early on in life,” Wu said. “I think of the first 1000 days of life as being an important period to prevent obesity and promote optimal health, and then later on, early adolescence is another critical window for intervention.”

For gastroenterologists, these findings carry direct clinical relevance. Specialists often encounter the downstream effects of obesity, including 

metabolic dysfunction-associated steatotic liver disease

. This positions them as important touchpoints for screening and intervention. However, Wu stressed that addressing food access challenges requires a team-based approach.

“Working with primary care physicians, working with our dietitians, social work, other patient health navigators, is critical because it does not by any means rely on the gastroenterologist alone, and we have found a team-based approach is what's most productive and collaborative in helping navigate healthy food access, at least in terms of children and for families,” she explained.

Looking ahead, the findings support a multilevel strategy to combat childhood obesity that integrates clinical screening with community-based interventions and policy-level changes. Expanding access to nutrition support programs, including “food is medicine” initiatives and Medicaid-covered services, may play a critical role in bridging gaps.

Editors’ note: Wu reports no relevant disclosures.

US Centers for Disease Control and Prevention. Childhood Obesity Facts. April 2, 2024. Accessed May 2, 2026. 

https://www.cdc.gov/obesity/childhood-obesity-facts/childhood-obesity-facts.html

Wu A, Arris IM, Luo M, et al. MULTILEVEL ASSOCIATIONS OF THE FOOD ENVIRONMENT WITH CHILD BODY MASS INDEX AND OBESITY. Presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, May 2-5, 2026.

Videos

Wu describes her research linking low food access and food insecurity to higher childhood obesity risk, highlighting the need for early, multilevel prevention strategies.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Why Food Access Matters in Childhood Obesity Prevention, With Allison Wu, MD, MPH

Basile Njei, MD, PhD, MPH, is an assistant professor at Yale School of Medicine.

Optimizing MASLD Screening in the Era of Liver-Directed Therapy

metabolic dysfunction-associated steatotic liver disease (MASLD)

 solidifies its position as the leading cause of chronic liver disease in the United States, a critical gap remains: most patients with clinically significant fibrosis still go undiagnosed. With the recent emergence of liver-directed therapies, the stakes of early identification have never been higher.

New research presented by Basile Njei, MD, PhD, MPH, an assistant professor at Yale School of Medicine, at Digestive Disease Week (DDW) 2026 in Chicago, IL, explores whether widespread screening using noninvasive tests (NITs) is not only clinically beneficial, but also economically justified in this new treatment era.

March 14, 2024: Madrigal Pharmaceuticals’ 

, an oral, thyroid hormone receptor (THR)-β selective agonist, approved as the first MASH therapy in combination with diet and exercise

injection 2.4 mg, a GLP-1 receptor agonist, approved as the second MASH therapy, again in combination with diet and exercise

In the past, most of the noninvasive tests were not cost effective, because you identify a patient with fibrosis, but then you don't have a treatment for it,” Njei explained to 

. “You diagnose more patients without treating them, and so the cost goes up without an improvement in the quality of life.”

He noted that MASLD carries risks that extend far beyond the liver, with affected patients facing an increased likelihood of cardiovascular events, kidney disease, and cancer. Despite this, many individuals remain undiagnosed until later stages of disease, limiting opportunities for intervention.

Traditionally, clinicians have relied on simple, accessible tools such as the FIB-4 score to assess fibrosis risk, followed by confirmatory imaging like transient elastography (TE) to evaluate liver stiffness. While effective, the broader implementation of these strategies has been limited in part by questions regarding cost-effectiveness, especially in an era when treatment options were lacking.

Now, with 2 US Food and Drug Administration approved treatment options in the forms of resmetirom (Rezdiffra) and semaglutide (Wegovy), Njei and colleagues conducted a decision-analytic Markov model informed by nationally representative NHANES data from 2017 to 2020. The study evaluated multiple screening pathways over 5- and 10-year horizons from a US payer perspective, comparing FIB-4, SAFE, ALADDIN, and LRS each followed by TE, against TE-only screening and usual care. The model also incorporated a phenotype-guided treatment strategy, assigning semaglutide to patients with obesity or diabetes and resmetirom to others with confirmed F2–F3 fibrosis.

Findings showed that across both time horizons, all lab-based NIT strategies followed by TE were cost-effective at a willingness-to-pay threshold of $50,000 per quality-adjusted life year (QALY), while TE-only screening was not. Among the approaches, SAFE + TE consistently emerged as the most cost-effective strategy, with incremental cost-effectiveness ratios (ICERs) of $8405/QALY at 5 years and $6864/QALY at 10 years, along with the highest net monetary benefit.

Of note, the study also highlighted the added value of a hybrid treatment approach. Compared to single-agent strategies, combining semaglutide and resmetirom based on patient phenotype yielded the greatest population-level benefit, underscoring the importance of personalized care in MASLD management.

While the results provide compelling, policy-relevant evidence supporting population-level screening, Njei noted that further real-world data are needed to confirm long-term outcomes, including reductions in liver decompensation, hepatocellular carcinoma, and mortality.

in management of these patients, number one. We can easily diagnose them now with simple lab tests, we have treatments that can help in reversing liver disease to a certain extent, and so that what we need moving forward is to get more data in the long term and to see how screening impacts long term outcomes. Because right now, we're still projecting, we're estimating, and in our study, for example, we are simulating scenarios of care. What will be important is for us to look long term.

Editors’ note: Njei reports no relevant disclosures.

Njei B, Lim JK. COST-EFFECTIVENESS OF NONINVASIVE TESTS FOR SCREENING MASLD-ASSOCIATED SIGNIFICANT LIVER FIBROSIS IN THE US POPULATION. Presented at Digestive Disease Week (DDW) 2026 in Chicago, IL, from May 2-5, 2026.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed May 2, 2026. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed May 2, 2026. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Njei explains the evolving treatment landscape for MASLD and how it impacts the cost-effectiveness of noninvasive tests for screening.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Strategic Alliance Partnership

Optimizing MASLD Screening in the Era of Liver-Directed Therapy, With Basile Njei, MD, PhD, MPH

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration (FDA) approvals of anifrolumab-fnia (Saphnelo) for subcutaneous self-administration in systemic lupus erythematosus (SLE) and lumateperone (Caplyta) for schizophrenia, clearance of Tandem Diabetes Care’s Control-IQ+ automated insulin delivery technology for use during pregnancy complicated by type 1 diabetes, Priority Review and Breakthrough Therapy Designation for bepirovirsen in chronic hepatitis B, and approval of AstraZeneza’s budesonide/glycopyrrolate/formoterol fumarate (BGF; BREZTRI Aerosphere) as the first single-inhaler triple-combination maintenance therapy for asthma in adult and pediatric patients 12 years of age and older.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of April 26, 2026—let’s jump in!

Anifrolumab (Saphnelo) Wins FDA Approval for Subcutaneous Self-Administration in SLE

On April 27, 2026, the FDA approved anifrolumab-fnia (Saphnelo) for subcutaneous self-administration via a once-weekly 120 mg autoinjector, the Saphnelo Pen, for adult patients with moderate to severe SLE receiving standard therapy. The decision was based on results from the phase 3 TULIP-SC trial.

Lumateperone sNDA Approved with Relapse Prevention Data in Schizophrenia

On April 26, 2026, the FDA approved a supplemental New Drug Application (sNDA) for lumateperone (Caplyta) based on long-term data supporting the prevention of relapse in adults with schizophrenia. Specifically, a phase 3 randomized withdrawal trial demonstrating a 63% reduction in relapse risk versus placebo over a 26-week double-blind treatment period.

FDA Clears Control-IQ+ for Use in Pregnancy With Type 1 Diabetes

On April 27, 2026, the FDA cleared Tandem Diabetes Care’s Control-IQ+ automated insulin delivery technology for use during pregnancy complicated by type 1 diabetes, expanding the label for the company’s t:slim X2 and Tandem Mobi systems. According to the Company, this makes Control-IQ+ the first commercially available automated insulin delivery system in the US with a pregnancy indication.

FDA Grants Bepirovirsen Breakthrough Therapy Designation, Priority Review for Chronic Hepatitis B

On April 28, 2026, the FDA accepted for Priority Review the New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide developed by GSK in partnership with Ionis Pharmaceuticals, for the treatment of adults with chronic hepatitis B. The Agency simultaneously granted bepirovirsen Breakthrough Therapy designation and established a PDUFA target action date of October 26, 2026.

If approved, bepirovirsen would represent the first therapy to achieve clinically meaningful functional cure rates in this population, addressing a significant gap in the current treatment landscape.

FDA Approves BGF Triple Therapy for Asthma in Patients 12 and Older

On April 28, 2026, the FDA approved AstraZeneza’s budesonide/glycopyrrolate/formoterol fumarate (BGF; BREZTRI Aerosphere) as the first single-inhaler triple-combination maintenance therapy for asthma in adult and pediatric patients 12 years of age and older. The decision marks the second approved indication for BGF, which received FDA clearance for chronic obstructive pulmonary disease in adults in 2020.

Articles

Multiple late-April 2026 FDA actions expanded access to therapies and devices across immunology, psychiatry, diabetes, virology, and pulmonary medicine. Anifrolumab gained a once-weekly subcutaneous autoinjector option for moderate-to-severe SLE based on phase 3 TULIP-SC. Lumateperone received an sNDA approval supported by phase 3 randomized withdrawal data showing reduced schizophrenia relapse risk. Tandem’s Control-IQ+ was cleared for type 1 diabetes in pregnancy. Bepirovirsen received Priority Review and Breakthrough Therapy designation in chronic hepatitis B, and BGF triple therapy was approved for asthma ages ≥12.

Stay updated with the latest healthcare breakthroughs, including notable FDA approvals and filings, in this week’s essential news roundup.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 04/26

Jignesh Shah, MD, is a gastroenterologist at Gastroenterology Consultants, PA.

New Tools, New Questions: Portable Gluten Sensors for Celiac Disease

As the management of celiac disease continues to rely almost entirely on strict dietary avoidance, emerging technologies are beginning to reshape how patients navigate daily life. Portable gluten detection sensors are generating both excitement and skepticism within the celiac community as new devices continue to enter the market.

, Jignesh Shah, MD, emphasized that while diagnosis remains the most challenging step in celiac disease management, the long-term burden often shifts to education and lifestyle adaptation. He noted that once confirmed, care transitions toward helping patients and families navigate dietary restrictions, behavioral modifications, and ongoing monitoring. This is where new tools, including portable gluten sensors, may offer meaningful support.

These devices, such as the NIMA sensor, rely on immunoassay-based technology similar to rapid antigen tests. A small sample of food is inserted into a disposable cartridge, which is then analyzed for gluten content. Results are displayed in a simple, user-friendly format, indicating whether the food is safe to consume.

According to Shah, this type of accessibility is key: “Easy interpretation and that kind of technology is what we need for consumers. Sometimes, we have to provide some reassurance. So devices like this are really, really needed as a tool for patients out there.”

In January 2026, Nima announced its next generation of the NIMA™ Gluten Sensor, branding it as the first handheld gluten detection device reengineered for faster, more dependable results. As described in a press release from the Company, it is the only portable solution capable of identifying all major gluten sources, including wheat, barley, and rye, down to 10 ppm with 99% accuracy, as confirmed through independent third-party laboratory testing.

“Once that diagnosis is done, essentially, what am I going to do as a gastroenterologist? I can just reassure, reassure, reassure, but when you start having devices like that, I can provide some objectivity, I can provide a resource, I can provide a tool,” he said.

However, Shah cautioned that it is still early in the adoption curve and stressed that these sensors should be viewed as adjunctive tools rather than definitive diagnostic instruments.

Clinically, he described particular value in targeted, situational use. For example, patients navigating social settings, such as dining out, may benefit from having an on-the-spot method to assess uncertain foods. He described the case of a college student newly diagnosed with celiac disease who wanted to maintain a normal social life. Rather than restricting her activities, Shah recommended selective use of the device in moments of doubt.

Additionally, these sensors may help address unexplained symptoms or persistently elevated serologic markers despite reported adherence to a gluten-free diet. In such cases, the device could help identify hidden sources of cross-contamination, offering both patients and clinicians greater insight into real-world exposures.

Looking ahead, Shah anticipates that adoption of these technologies will grow, though incorporation into formal guidelines may take time and require robust clinical data. For now, he believes the value lies in their ability to fill a gap in patient support.

Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. The American Journal of Gastroenterology 118(1):p 59-76, January 2023. doi:10.14309/ajg.0000000000002075

Nima. NIMA Partners Introduces the Next-Generation NIMA Gluten Sensor with 99% Accuracy Across All Major Gluten Sources. January 12, 2026. Accessed May 2, 2026. 

https://www.globenewswire.com/news-release/2026/01/12/3216836/0/en/nima-partners-introduces-the-next-generation-nima-gluten-sensor-with-99-accuracy-across-all-major-gluten-sources.html

Shah describes the science and real-world use of gluten sensors, with insights on how these tools may support patients with celiac disease without replacing standard care.

The Emerging Role of Gluten Detection Sensors in Celiac Disease Care, With Jignesh Shah, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

 highlighted a diverse series of developments across the 

 landscape, spotlighting recent regulatory momentum, emerging clinical findings, and broader conversations shaping the future of skincare.

-related activity, with multiple supplemental New Drug Applications (sNDAs) and expanded indications targeting increasingly specific patient populations, from infants living with atopic dermatitis to adolescents with chronic hand eczema and adults with alopecia areata.

In the following review of April 2026 dermatology news, the updates reflect the continued push toward earlier intervention and age-specific treatment strategies happening in the dermatology space, as well as a growing emphasis on addressing unmet needs in pediatric care:

Roflumilast Cream 0.05% sNDA Submitted to FDA for Infants Down to 3 Months with Atopic Dermatitis

The FDA received an sNDA for the broadening of roflumilast cream 0.05% (Zoryve) to treat infants with mild to moderate atopic dermatitis down to the age of 3 months. The sNDA was announced on April 27 by Arcutis Biotherapeutics, with the submission being backed by data drawn from a pair of open-label trials evaluating once-daily treatment with roflumilast cream 0.05% in infants.

Upadacitinib sNDA Submitted to FDA for Severe Alopecia Areata

On April 28, AbbVie announced its own sNDA submission for upadacitinib (Rinvoq) as a treatment for severe alopecia areata among adult and adolescent patients with the hair loss condition. The Company’s submission of upadacitinib for alopecia areata in this patient cohort was supported by a set of replicate phase 3 analyses from the UP-AA clinical trial program, with 15 mg and 30 mg once-daily doses having been evaluated by investigators.

FDA Expands Dupilumab to Children Aged 2 to 11 Years With Uncontrolled CSU

On April 22, the FDA approved dupilumab (Dupixent) as a therapy for children aged 2 - 11 years with chronic spontaneous urticaria (CSU) who also remain symptomatic despite H1 antihistamine treatment. This joint announcement from Regeneron and Sanofi means the drug’s indication for CSU is extended to adults and adolescents aged 12 years and older. Dupilumab thus became the first biologic medicine in the US for young children suffering from uncontrolled chronic spontaneous urticaria, according to the chief scientific officer at Regeneron.

FDA Accepts Delgocitinib sNDA for Chronic Hand Eczema in Adolescents Aged 12–17

In another FDA news release, the agency accepted an sNDA for delgocitinib (Anzupgo) cream as a treatment for patients with moderate-to-severe chronic hand eczema (CHE), specifically adolescents aged 12 - 17 years of age. The decision followed the DELTA TEEN, 16-week, double-blind, vehicle-controlled phase 3 trial’s conclusion, with investigators having assessed 12 - 17-year-olds with TCS-inadequate/inappropriate disease on twice-daily delgocitinib.

ABCs in Dermatology: Late Breaking Data Spotlight at AAD 2026

During April’s special edition episode of ABCs in Dermatology, the podcast’s hosts Chris Bunick, MD, PhD, of Yale School of Medicine, and Lindsay Ackerman, MD, of US Dermatology Partners, gave a break down several key late-breaking trials from the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, providing their views on additional data of note across various dermatologic disease states.

Skin of Color Savvy: Updates on the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

In an April Skin of Color Savvy podcast episode, hosted by Skin of Color Society (SOCS) leaders and produced by HCPLive, SOCS leader Vinod Nambudiri, MD, MBA, MPH, a medical dermatologist at Brigham and Women’s Hospital and leader in dermatology education, provided an interview on-site at the AAD meeting regarding his team’s ongoing efforts to improve representation in clinical training resources, as well as several emerging insights on artificial intelligence (AI) and physician well-being.

The Medical Sisterhood: Exposure is Power-Women in Medicine Creating Opportunity, With Elizabeth Kiracofe, MD

The most recent episode of The Medical Sisterhood podcast included a conversation between host Mona Shahriari, MD, assistant clinical professor of dermatology at the Yale University School of Medicine, and Elizabeth A. Kiracofe, MD, a board-certified dermatologist and founder of Airia Comprehensive Dermatology. The 2 conducted a candid conversation centered on providing for the community, career evolution, and redefining success as a clinician.

April’s dermatology updates emphasized accelerated regulatory activity alongside educational and professional discourse. Multiple FDA submissions and approvals targeted earlier, age-stratified intervention, including infants with atopic dermatitis, adolescents with chronic hand eczema, and pediatric chronic spontaneous urticaria refractory to H1 antihistamines. Late-stage clinical datasets supported pipeline expansion into alopecia areata and additional pediatric indications. Concurrently, meeting-based and podcast content elevated late-breaking AAD 2026 trial signals, improved skin-of-color representation in training resources, and explored AI, clinician well-being, and women’s leadership trajectories in dermatology.

This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

7 Dermatology Headlines You Missed in April 2026

Elizabeth Kiracofe, MD, speaks in this segment of her recent The Medical Sisterhood podcast about her career and other community initiatives.

Getting Involved in the Community as a Dermatologist, With Elizabeth Kiracofe, MD

Rachael Sood, NP, is a diabetes nurse practitioner and Owner and CEO of The Diabetes Collective.

Sood shares her thoughts on the recent announcement by the FDA, limiting pharmacies’ ability to compound semaglutide, tirzepatide, and liraglutide from bulk substances.

FDA News

Type 2 Diabetes

FDA Proposes Exclusion of Multiple GLP-1 RAs from Bulks List, With Raechel Sood, NP

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

APOL1 research is driving precision nephrology, but prediction gaps and equity challenges still limit clinical impact.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

APOL1-Mediated Kidney Disease: From Genetic Discovery to the Edge of Precision Medicine

Physician and CEO, Chicago Allergy Center, and board director at American Lung Association

The first single-inhaler ICS/LABA/LAMA combination for asthma adds a mechanistically distinct bronchodilator to a well-established inhaled backbone.

BGF Triple Therapy FDA Approval Expands Asthma Options for Underserved Patients, With Juanita Mora, MD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA expands lumateperone for relapse prevention in schizophrenia, White House boosts psychedelics research, and AI reshapes psychiatry care debates in April 2026.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

5 Psychiatry Headlines You Missed in April 2026

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

April 2026 saw new data from pivotal clinical trials and a new approval in asthma.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

5 Pulmonology Headlines You Missed in April 2026

Experts debate when to start growth hormone after cancer, share pediatric vs adult wait times, and offer tips on long‑acting GH dosing.

Growth Hormone Deficiency in Cancer Survivors

Insurance barriers and missing records complicate adult growth hormone therapy, as experts urge better documentation, transition clinics, and patient-centered care to improve outcomes.

Navigating Barriers in Adult GHD Management

How to keep growth hormone deficiency patients on track when moving to adult care—cutting waitlists, dropouts, and insurance delays.

Transitioning GHD Patients from Pediatric to Adult Care — Challenges and Best Practices

Clinicians explain practical weekly growth hormone dosing—weight-based, pen-device rounding, and IGF‑1 checks—plus how puberty, fatigue, and growth velocity guide stopping therapy.

Latest News

Why Food Access Matters in Childhood Obesity Prevention, With Allison Wu, MD, MPH

Optimizing MASLD Screening in the Era of Liver-Directed Therapy, With Basile Njei, MD, PhD, MPH

The HCPFive: Top News for Healthcare Providers from the Week of 04/26

The Emerging Role of Gluten Detection Sensors in Celiac Disease Care, With Jignesh Shah, MD

7 Dermatology Headlines You Missed in April 2026